The present study addressed the impact of human papillomavirus (HPV), p14, and the product of the retinoblastoma gene (pRb) HPV-infected cases significantly correlated with high expression of p14 (P < .01) and p16 (P < .01 Vulvar squamous cell carcinomas are divided into 2 subgroups with different causes-one related to human papillomavirus (HPV) infection and one that is not. 1-3 The patient groups differ in age, tumor histologic features, and prognosis. Overall, vulvar carcinomas show HPV infection in 9% to 57% of cases. [4] [5] [6] [7] [8] Patients with HPV-associated tumors tend to be diagnosed at an earlier age than those with non-HPV-associated vulvar carcinomas. 1-3,9,10 The conventional vulvar carcinoma is of the keratinizing/nonkeratinizing subtype, normally negative for HPV infection, whereas the basaloid and verrucoid carcinomas show HPV infection in the majority of cases. 2, 3 Previous studies have indicated a better prognosis for patients with HPV+ vulvar cancer, 11,12 whereas others have found no prognostic significance associated with HPV status. 3, 7, 13 The product of the retinoblastoma gene (pRb) has a major role in the cell cycle. When phosphorylated, the pRb releases the transcription factor E2F, which consequently activates genes involved in DNA synthesis and cell cycle progression. 14, 15 In cervical cancer cell lines in which pRb has been inactivated by the HPV E7 oncoprotein, the levels of p16 INK4a (p16) are increased. 16 In a previous study, Knopp et al 17 found up-regulation of p16 protein in 31% of vulvar carcinomas, which may be due to infection with HPV. High expression of p16 also was associated with longer disease-related survival. p16 and p14 ARF (p14) are encoded by the same locus on chromosome 9p21, 18 and they are growth suppressive through 2 pathways: the INK4-cyclin/cdk-Rb and ARF-MDM2-p53 pathways, respectively. 19 Previous studies have revealed that the network in which p14 takes part is abrogated in most human tumors (reviewed by Sherr 19 ). To our knowledge, the prognostic impact of p14 and its correlation with HPV status has not been studied in vulvar carcinoma.
Vulvar squamous cell carcinomas are divided into 2 subgroups with different causes-one related to human papillomavirus (HPV) infection and one that is not. [1] [2] [3] The patient groups differ in age, tumor histologic features, and prognosis. Overall, vulvar carcinomas show HPV infection in 9% to 57% of cases. [4] [5] [6] [7] [8] Patients with HPV-associated tumors tend to be diagnosed at an earlier age than those with non-HPV-associated vulvar carcinomas. [1] [2] [3] 9, 10 The conventional vulvar carcinoma is of the keratinizing/nonkeratinizing subtype, normally negative for HPV infection, whereas the basaloid and verrucoid carcinomas show HPV infection in the majority of cases. 2, 3 Previous studies have indicated a better prognosis for patients with HPV+ vulvar cancer, 11, 12 whereas others have found no prognostic significance associated with HPV status. 3, 7, 13 The product of the retinoblastoma gene (pRb) has a major role in the cell cycle. When phosphorylated, the pRb releases the transcription factor E2F, which consequently activates genes involved in DNA synthesis and cell cycle progression. 14, 15 In cervical cancer cell lines in which pRb has been inactivated by the HPV E7 oncoprotein, the levels of p16 INK4a (p16) are increased. 16 In a previous study, Knopp et al 17 found up-regulation of p16 protein in 31% of vulvar carcinomas, which may be due to infection with HPV. High expression of p16 also was associated with longer disease-related survival. p16 and p14 ARF (p14) are encoded by the same locus on chromosome 9p21, 18 and they are growth suppressive through 2 pathways: the INK4-cyclin/cdk-Rb and ARF-MDM2-p53 pathways, respectively. 19 Previous studies have revealed that the network in which p14 takes part is abrogated in most human tumors (reviewed by Sherr 19 ). To our knowledge, the prognostic impact of p14 and its correlation with HPV status has not been studied in vulvar carcinoma.
The expression of pRb has been the subject of previous studies on vulvar carcinomas. 6, [20] [21] [22] The loss of Rb expression has been found to increase with stage. 21 However, no prognostic value for pRb in vulvar carcinoma has been found. 6 In a large number of tumors, the present study addressed the connection of HPV, p16, p14, and pRb and the impact of high-risk HPV DNA, p14, and pRb in relation to clinicopathologic variables and prognosis in vulvar squamous cell carcinoma.
Materials and Methods

Tumor Materials
A retrospective study of 217 primary tumors and 7 metastases from 217 patients with squamous cell carcinoma of the vulva undergoing surgery at the Norwegian Radium Hospital, Oslo, from January 1977 to October 1991, was performed. Inclusion criteria for metastases were high expression of p16 or an HPV+ corresponding primary tumor. No chemotherapy or radiotherapy was given before surgery. Postoperative irradiation was given to 46 (21.2%) of the patients. The median age at diagnosis was 72 years (range, 35-96 years).
All patients were followed up until death or until 5 years after study inclusion. Of the 217 patients, 64 (29.5%) died of vulvar cancer within 5 years after inclusion. Clinical data and follow-up information were obtained from medical records and Statistics Norway. The Norwegian Board of Health and the Data Inspectorate approved the study. All tumors were staged according to the International Federation of Gynecology and Obstetrics (FIGO) classification. 23 In 3 previous studies, primary tumors and metastases were studied for the expression of p16, p21, and p27 and cyclins A, D1, D3, and E. 17, 24, 25 Histologic specimens were reviewed by one of us (J.M.N) who had no access to clinical information. The tumors were classified and graded according to World Health Organization recommendations. 26 Depth of stromal invasion was measured by an ocular micrometer from the top of the nearest dermal papilla to the deepest point of stromal penetration. Vessel invasion was observed within unquestionably endothelium-lined spaces. As control specimens, samples of normal vulva were obtained from 10 patients undergoing surgery for benign gynecologic diseases.
Immunohistochemical Analysis
Single Immunostaining Method
Sections for immunohistochemical analysis were stained using the biotin-streptavidin-peroxidase method (Supersensitive Immunodetection System, LP000-UL, BioGenex, CA) and the OptiMax Plus Automated Cell Staining System (BioGenex).
Deparaffinized sections were microwaved in 10 mmol/L of citrate buffer, pH 6.0, to unmask the epitopes and treated with 1% hydrogen peroxide (H 2 O 2 ) for 10 minutes to block endogenous peroxidase. The sections were incubated with polyclonal antibodies pRb, detecting only ser 807/811 phosphorylated pRb (No. 9308, dilution 1:50; 0.52 µg IgG/mL; Cell Signaling Technology, Beverly, MA); pRb, recognizing phosphorylated and nonphosphorylated forms of pRb p110 (C-15, dilution 1:800; 0.25 µg IgG/mL; Santa Cruz Biotechnology, Santa Cruz, CA); and monoclonal antibody p14 (clone 14P02, dilution 1:3,000; 0.07 µg IgG1/mL; NeoMarkers, Fremont, CA) for 30 minutes at room temperature. The sections then were incubated with biotin-labeled secondary antibody (dilution 1:30) and streptavidin-peroxidase (dilution 1:30) for 20 minutes each. Tissue samples were stained for 5 minutes with 0.05% 3'3-diaminobenzidine tetrahydrochloride (DAB) freshly prepared in 0.05 mol/L of tris(hydroxymethyl)-aminomethane buffer, pH 7.6, containing 0.024% H 2 O 2 and then counterstained with hematoxylin, dehydrated, and mounted in Diatex (Becker Industrifärg, Marsta, Sweden). All dilutions of antibody, biotin-labeled secondary antibody, and streptavidin-peroxidase were made with phosphate-buffered saline, pH 7.4, containing 1% bovine serum albumin.
All series included positive control samples. Negative control samples included replacement of the polyclonal primary antibody with normal rabbit IgG, whereas negative control samples for the monoclonal antibody were performed using mouse myeloma protein of the same subclass and concentration as the monoclonal antibody. All control samples gave satisfactory results.
Only distinct nuclear staining was considered positive. Four semiquantitative classes were used to describe the number of positively stained tumor cells: none, fewer than 5% of the cells, 5% to 50% of the cells; and more than 50% of the cells. Sections were scored by 2 independent observers (S.K. and R.H.) with no knowledge of clinical data. Conflicting results were reviewed until final agreement was achieved. Based on the staining pattern observed in normal vulvar epithelium, cutoffs for each of the proteins were defined. Protein levels were classified as high for p14 when any staining was seen in the tumor and for total pRb and phosphorylated pRb, when 5% or more of the tumor cells were positive.
Single In Situ Hybridization Method
In situ hybridization was carried out with biotinylated probes against HPV-16, HPV-18 27, 28 (a gift from Harald zur Hausen, MD, PhD, and Ethel-Michele de Villiers, PhD, Heidelberg, Germany), HPV-31, and HPV-33 (Ferring Diagnostic, Malmö, Sweden) and an alkaline phosphatase anti-alkaline phosphatase (APAAP) detection system as previously described. 29 Briefly, sections from formalin-fixed, paraffin-embedded material were treated sequentially with Proteinase K (700 µg/mL), 0.2% glycine, and 4% paraformaldehyde. After probe and cellular DNA were denatured together by heating at 95°C for 10 minutes, the slides were hybridized for 18 to 22 hours at 37°C. Tissue sections were given high-stringency washes before hybridized DNA was detected using sequential incubation with mouse antibiotin, rabbit antimouse IgG, and APAAP. The alkaline phosphatase reactions were developed using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate as chromogens.
All series included positive control samples. Negative control experiments were performed using pBR 322 DNA labeled with biotin. These control experiments gave satisfactory results.
Double Immunostaining and In Situ Hybridization Method
Double staining was carried out using a combination of the immunostaining method DAKO EnVision+ System, peroxidase (DAB) (K4007, DAKO, Carpinteria, CA), and the APAAP in situ hybridization method. 29 Peroxidase was used as the label for the p16 antibody (clone 16P04, NeoMarkers) and alkaline phosphatase for the HPV-16 and HPV-33 probes. Deparaffinized sections were microwaved in 10 mmol/L of citrate buffer, pH 6.0, for 20 minutes to unmask the epitopes and then treated with 0.03% H 2 O 2 for 5 minutes to block endogenous peroxidase. The sections were incubated with different dilutions (1:25 and 1:50) of p16 antibody for 30 minutes at room temperature and then with peroxidase-labeled polymer conjugated to goat antimouse for 30 minutes. Tissue samples were stained for 10 minutes with DAB.
After staining with DAB, the sections were microwaved in 10 mmol/L of citrate buffer, pH 6.0, twice for 5 minutes each time to exclude the possibility of a cross-reaction. The sections then were treated sequentially with Proteinase K (700 µg/mL), 0.2% glycine, and 4% paraformaldehyde. After HPV-16 or HPV-33 probes and cellular DNA were denatured together by heating at 95°C for 10 minutes, the slides were hybridized for 18 to 22 hours at 37°C. Tissue sections were given high-stringency washes before hybridized DNA was detected using sequential incubation with mouse antibiotin, rabbit antimouse IgG, and APAAP. The alkaline phosphatase was detected by using a mixture of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate for 45 minutes in the dark. Tissue sections were mounted in glycerin jelly.
Control experiments included omission of the p16 antibody or omission of the HPV-16 or HPV-33 probes. These control experiments gave satisfactory results.
Statistical Analyses
The Pearson χ 2 test was used to compare the distribution of various patient characteristics by expression of p14, total pRb, phosphorylated pRb, and HPV DNA. Survival rates were calculated by using the method described by Kaplan and Meier. 30 Disease-specific survival rates were based on death due to vulvar cancer only. Univariate and multivariate relative risks (RRs) of dying were calculated by using Cox proportional hazards regression. Patients were censored after 5 years. In multivariate analysis, forward stepwise regression with a P value of .05 as the inclusion criterion was used. All calculations were performed using the SPSS 12.0 statistical software package (SPSS, Chicago, IL). A significance level of .05 was chosen.
Results
In normal vulvar epithelium, no p14 expression was observed, whereas phosphorylated pRb stained positively in fewer than 5%. Five cases of normal vulvar epithelium showed 5% to 50%, and 5 cases showed 50% or more positive staining for total pRb. Phosphorylated pRb staining was seen in the basal and parabasal layers of normal vulvar epithelium, whereas total pRb staining was seen in the basal, parabasal, middle, and top layers.
❚Table 1❚ gives the immunohistochemical expression results for p14, total pRb, and phosphorylated pRb in vulvar squamous cell carcinomas. High p14 expression was seen in 78 cases (35.9%) ❚Image 1A❚. In a previous study, Knopp et al 17 DNA were found in 2 cases (0.9%) each. No infection with HPV-31 was identified. By using a double-staining method combining immunohistochemical analysis and in situ hybridization, p16 protein and HPV-16 DNA were identified in the same cells in 5 primary tumors and 1 metastasis ❚Image 1D❚, whereas p16 protein and HPV-33 DNA were colocalized in the same neoplastic cells in 1 primary tumor and 1 metastasis. Of the virus-infected samples, 100% had a punctate signal, indicating integrated virus DNA (Image 1C). In addition, a diffuse signal was found in 20 (47%) of the HPV-16+ cases ❚Image 2A❚ and 2 (100%) of the HPV-33+ cases ❚Image 2C❚. Of the 7 metastases examined, HPV-16 DNA ❚Image 2B❚ was found in 3 metastases and HPV-33 DNA ❚Image 2D❚ was found in 1 metastasis. The metastases expressed the same HPV genotype and the same punctate and diffuse signal as the corresponding primary tumors (Images 2A and 2C).
Keratinizing/nonkeratinizing squamous cell carcinoma was found in 198 cases (91.2%), whereas basaloid and verrucoid carcinomas were found in 14 (6.5%) and 5 (2.3%), respectively. HPV DNA was found in 18% of the keratinizing/nonkeratinizing tumors, in 40% of the verrucoid, and in 71% of the basaloid tumors.
❚Table 2❚ shows the expression results for HPV DNA, p14, and phosphorylated pRb in relation to clinicopathologic variables. HPV+ cases correlated significantly with high expression of p14 (P < .01), p16 (P < .01), p21 (P = .02), p27 (P < .01), and cyclin A (P < .01) and low expression of p53 (P < .01), cyclin D1 (P < .01), cyclin D3 (P < .01), and cyclin E (P = .01). High expression of p14 correlated significantly with high expression of p16 (P = .01), whereas a high level of phosphorylated pRb was associated with high levels of total pRb (P = .01) and cyclin A (P = .02). There was a statistically significant correlation between HPV+ cases and grade of differentiation (P < .01), lymph node status (P = .03), and depth of invasion (P = .01) with HPV DNA positivity in poorly differentiated tumors, lymph node-negative cases, and tumors with invasion depth of less than 4 mm. Basaloid carcinomas were associated with HPV infection (P < .01). A higher proportion of younger patients have HPV-associated (P < .01) and p14+ tumors (P = .02) than older patients. In univariate analyses, HPV+ cases showed an RR of 0.4 (95% confidence interval, 0.2-0.9; P = .02) of dying of vulvar cancer within 5 years compared with HPV-cases ❚Figure 1A❚.
p14 expressing cases showed a RR of 0.5 (95% confidence interval, 0.3-0.9; P = .02) compared with the p14-cases ❚Figure 1B❚. pRb, phosphorylated pRb, and physical state of HPV DNA had no prognostic significance.
In multivariate analyses, HPV status and p14 expression were added to the variables infiltration of vessel, lymph node metastasis, age, tumor diameter, and depth of invasion. HPV status did not reach prognostic significance. The independent prognostic variables were p14 (P = .01), tumor diameter (P = .01), lymph node metastasis (P < .01), and infiltration of vessel (P < .01) ❚Table 3❚, with high expression of p14 indicating longer disease-specific survival.
In the HPV-cases, p14 and p53 expression showed a significant correlation (P < .01). Of the 60 HPV-tumors with low expression of p53, only 9 (15%) showed high expression of p14. Of the HPV-/p14-cases, 66% of the patients were 70 years or older, whereas of the HPV+/p14+ cases, 63% of the patients were younger than 70 years. Expression of p14 significantly indicated good disease-specific survival (P = .03) in HPV-cases ❚Figure 1C❚, whereas p14 expression, although not statistically significant, signaled a worse prognosis in HPV+ cases ❚Figure 1D❚. In HPV-cases with high expression of p53, the prognostic value for p14 in multivariate analysis was even more distinct (P < .01) ❚Figure 1E❚ and ❚Table 4❚.
Discussion
In the present study, HPV DNA was found in 21.7% of the cases. Previous studies on vulvar carcinomas have reported HPV infection in 9% to 57% of cases, depending on the detection method used. [4] [5] [6] [7] [8] In our study, a nonreactive in situ hybridization method with a high sensitivity identifying 1 or 2 copies of HPV-16 DNA in SiHa cells was used. 31 No HPV DNA products were obtained using the polymerase chain reaction method, probably owing to the fixation in acid formalin and long-term storage of paraffin-embedded tissue samples, which may influence the DNA quality. 32 Vulvar carcinomas are divided into 3 histologic subtypes-keratinizing/nonkeratinizing, basaloid, and verrucoid. Keratinizing/nonkeratinizing squamous cell carcinomas accounted for 91.2% of the tumors in our study, whereas basaloid and verrucoid carcinomas represented 6.5% and 2.3%, respectively. This histologic distribution is in accordance with that found by others. 33 Basaloid and verrucoid carcinomas have been found to contain HPV DNA in 50% to 100% of cases, 1,2,10,34 whereas keratinizing/nonkeratinizing carcinomas show HPV infection in only 4% to 21% of cases, some even containing verrucoid components or features of basaloid carcinoma. 2, 10 This is in accordance with the findings of the present study, in which HPV DNA was found in 71% of basaloid, 40% of verrucoid, and 18% of keratinizing/nonkeratinizing tumors. Others have found no relation between tumor subtype and HPV infection. 35 We found a significant inverse correlation between the presence of HPV DNA and the expression of p53. Among the HPV-tumors, 64% had high expression of p53, whereas only 23% of the HPV+ tumors showed high p53 expression. This is in accordance with a study by Kagie et al. 13 In the HPV+ cases, HPV E6 is able to bind to the transcription factor p53, induce its degradation, and retain p53 in the cytoplasm. [36] [37] [38] In the HPV-cancers, mutation in p53 may compensate for the absence of HPV E6. 8, 12, 39 In our study, high expression of p16 correlated significantly with the presence of HPV DNA. Of the HPV+ tumors, 85% had high expression of p16, whereas only 15% of the HPV-tumors had high expression of p16. These findings are in accordance with those of other studies on vulvar 40, 41 and cervical carcinoma. 42 It has been shown that p16 levels are increased in cervical cancer cell lines in which pRb has been inactivated by the HPV E7 oncoprotein. 16 By using a doublestaining method combining immunostaining and in situ hybridization, we identified p16 protein and HPV DNA in the same cells in vulvar carcinomas. For the first time, we found correlations between HPV infection and p14 and between p14 and p16 in vulvar carcinomas. This may be due to the association of HPV E7 oncoprotein with pRb, resulting in an increase of free E2F and up-regulation of p16 and p14, 43 which are encoded by the same INK4a/ARF locus. 18 The HPV E7 leads to constitutive expression of cyclin A throughout the cell cycle. 44, 45 This is in accordance with the present study in which 91% of the HPV DNA+ tumors showed high expression of cyclin A. The D cyclins showed reduced expression in the HPV+ tumors compared with the HPV-tumors in the present study. These findings are in accordance with those of previous studies in which HPV E7 reduced or did not affect cyclin D1 gene expression. 45, 46 In the present study, 96% of the HPV+ tumors showed low expression of cyclin E. This contradicts findings of previous studies in which the HPV E7 protein increased cyclin E-cdk2 activity, in part via increased synthesis of cyclin E, 44, 45, 47 but also through inactivation of the cdk inhibitors p27 48 and p21. 49, 50 However, it has been shown that HPV-18 E7-expressing keratinocytes accumulate high levels of p27 and cyclin E/p21 or enter the S phase. 51 On S-phase entry, cyclin E is down-regulated. 52 Given the combination of low expression of cyclins D1, D3, and E and high expression of cyclin A in the majority of the HPV+ tumors in the present study, it may be speculated that a significant portion of the cells were fixated in the S phase. Jones et al 50 reported that HPV-16 E7 could exist in complexes containing p21 and so abrogate p21-mediated cdk2 inhibition in cells with elevated levels of p21. Thus, it may be speculated that the p21 found elevated in the majority of the HPV+ cases in our study may be inactive.
Women with HPV-associated vulvar carcinoma tend to be diagnosed at an earlier age than those with non-HPV-associated vulvar carcinoma. 2, 10, 35 The present study supports this inclination because 32% of patients up to 70 years of age had tumors containing HPV DNA, whereas it was found in only 13.3% of the tumors from patients 70 years or older. Furthermore, high expression of p14 was found in 45% of the vulvar carcinomas from patients younger than 70 years, whereas only 28.3% of the tumors among the patients 70 years or older showed high expression of p14. In a previous study, Knopp et al 17 found that high p16 expression was correlated with decreasing patient age. The close relationship in HPV status, p14 and p16 expression, and age in our patient population is in accordance with our findings that HPV+ vulvar carcinomas showed up-regulation of p16 and p14 proteins. Of the patients with HPV DNA-tumors, 32% died of vulvar carcinoma within 5 years, whereas among the patients with HPV DNA+ tumors, the rate was 17%. Furthermore, 54% of patients with HPV-tumors were free of lymph node metastases, whereas of the patients with HPV+ tumors, 78% were free of lymph node metastases. These findings are in accordance with those of previous studies that have indicated a better prognosis for patients with HPV+ tumors. 11, 12 Other investigators found no prognostic significance connected to HPV status. 3, 7, 13 All 47 HPV+ vulvar carcinomas in the present study had a punctate in situ hybridization signal indicating integrated HPV DNA, whereas 23 (49%) also had a diffuse signal, indicating episomal HPV DNA. Previous studies have found integration of HPV DNA into host cellular DNA to be associated with neoplastic progression. 31, [53] [54] [55] [56] In a study on low-stage cervical cancer, disease-free survival was shorter for women whose tumors had only integrated HPV DNA than for women in whom the tumors had combined episomal and integrated HPV DNA. 57 In another series of cervical cancer no correlation between HPV integration and clinical characteristics was found. 58 The physical state of HPV DNA did not correlate with survival in the present study.
For the first time, we found a significant correlation between the expression of p14 and the 5-year disease-specific survival, with the expression of p14 signaling a better prognosis. When analyzing the HPV+ and HPV-cases separately, p14 expression significantly indicated longer disease-specific survival in HPV-cases, whereas p14 expression, although not statistically significant, signaled a worse prognosis in HPV+ cases. These findings fit well with the fact that p14 leads to cell cycle arrest through the stabilization of p53 in HPV-cells, whereas in HPV+ cells, HPV E6 inactivates p53 and, consequently, abrogates cell cycle arrest by p14. 59 In HPV-cases with high expression of p53, the prognostic value for p14 was even more distinct. The independent prognostic predictive value of p14 for all cases was validated in a multivariate analysis with infiltration of vessel, lymph node metastasis, and tumor diameter as the complementing prognostic predictors.
Our study shows a close connection between HPV infection and the expression of p16 and p14 in vulvar carcinoma. For the first time, we showed that p14 is a prognostic indicator for vulvar squamous cell carcinoma, with high expression of p14 indicating longer disease-specific survival.
In patients with HPV-tumors expressing high levels of p53, low p14 expression indicates the poorest 5-year disease-specific survival.
